FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PTO FORM PAT-1449)
Patent and Trademark Office



45

Atty. Dkt. No.	M#	Client Ref.
	018743	0276324

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Katherine A. High, et al.

COPY OF PAPERS ORIGINALLY FILED

Appln. No.: 09/589,589

Filing Date: June 8, 2000

Date: March 6, 2002 Page 1 of 2

Examiner: TBA | Group Art Unit: TBA

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (If appropriate)
	AR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name		English Abstract		Translation Readily Available	
							Enclosed	No	Enclose	N
	BR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

BV	CR	Cater, 1992, "Adeno-associated Virus Vectors," Biotechnology, 3: 533-539. ✓
	DR	Dai, et al., 1995 "Cellular and Humoral Immune Responses to Adenoviral Vectors Containing Factor IX Gene: Tolerization of Factor IX and Vector Antigens Allows for Long-term Expression," Proc. Natl. Acad. Sci. USA, 92:1401-1405. ✓
	ER	High, et al., 1995, "Factor IX In: Molecular Basis of Thrombosis and Hemostasis," High and Roberts, (eds.), Marcel Dekker, Inc. ✓
	FR	Herzog, et al., 1997, "Stable Gene Transfer and Expression of Human Blood Coagulation Factor IX After Intramusular Injection of Recombinant Adeno-associated Virus," Proc. Natl. Acad. Sci. USA, 94:5804-5809. ✓
	GR	Herzog, et al., 1999, "Long-term Correction of Canine Hemophilia B by Gene Transfer of Blood Coagulation Factor IX Mediated by Adeno-associated Viral Vector, "Nature Medicine, 5:56-63. ✓
	HR	Herzog and High, 1999, "Adeno-associated Vrius-mediated Gene Transfer of Factor IX for Treatment of Hemophilia B by Gene Therapy," In: Thrombosis and Hemostasis, 1999 State of the Art, Hoyer L(ed.), 82:540-546. ✓
	IR	Kaplitt, et al., 1994, Long-term Gene Expression and Phenotypic Correction Using Adeno-associated Virus Vectors in the Mammalian Brain, "Nature Genetics, 8:148-154. ✓
	JR	Kay, et al., 1993, "In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs," Science, 262:117-119. ✓
	KR	Kay, et al., 1997,"Transient Immunomodulation with Anti-CD40 Ligand Antibody and CTLA41g Enhances Persistence and Secondary Adenovirus-mediated Gene Transfer Into Mouse Liver," Proc. Natl. Acad. Sci. USA, 94:4686-4691. ✓
	LR	Kessler, et al., "Gene Delivery to Skeletal Muscle Results in Sustained Expression and Systemic Delivery of a Therapeutic Protein," Proc. Natl. Acad. Sci. USA, 93: 14082-14087. ✓
	MR	Matsushita, et al., 1998, "Adeno-associated Virus Vectors can be Efficiently Produced without Helper Virus," Gene Therapy, 5:938-945. ✓
	NR	Matsushita, et al.,1999, "Proceedings of the 2nd Annual American Society of Gene Theraphy, Washington, DC, June 9-13, p.2a. ✓
PL	OR	Nakai, et al., 1998, "Adeno-associated Viral Vector-mediated Gene Transfer of Human Blood Coagulation Factor IX Into Mouse Liver," Blood, 91: 4600-4607. ✓

Paul Lu 5/13/02

	PR	Skulimowski, et al., 1995, "Adeno-associated Virus: Integrating Vectors for Human Gene Therapy," Methods in Molecular Genetics, 7:7-12.	
	QR	Tripathy, et al., 1996, "Immune Responses to Transgene-encoded Proteins Limit the Stability of Gene Expression after Injection of Replication-defective Adenovirus Vectors," Nature Medicine, 2:545-550.	
	RR	Tripathy, et al., 1996, "Long –term Expression of Erythropoietin in the Systemic Circluation of Mice after Intramuscular Injection of a Plasmid DNA Vector," Proc. Natl. Acad. Sci. USA, 93:10876-10880.	
	SR	Xiao, et al., Efficient Long-term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Adeno-associated Virus Vector," Journal of Virology, 70:8098-8108.	
	TR	Yang, et al., 1996 "Immunology of Gene Therapy with Adenoviral Vectors in Mouse Skeletal Muscle," Human Molecular Genetics, 5:1703-1712.	
	UR		
	VR		
	WR		
	XR		
	YR		
	ZR		
	AAR		
	BBR		
	CCR		
	DDR		
	EER		
	FFR		
	GGR		
	HHR		
	IIR		
	JJR		

OIPE
MAR 18 2002
PATENT & TRADEMARK OFFICE
COPY OF PAPERS ORIGINALLY FILED

Examiner [signature]	Date Considered: 5/31/03

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.